BRIEF-Astellas Pharma Inc: Iveric Bio Announces Positive 24-Month Topline Results From Phase 3 Study Of Izervay (Avacincaptad Pegol Intravitreal Solution) For Geographic Atroph

Reuters2023-09-19

Sept 19 (Reuters) - Astellas Pharma Inc :

* ASTELLAS PHARMA INC - IVERIC BIO ANNOUNCES POSITIVE 24-MONTH TOPLINE RESULTS FROM PHASE 3 STUDY OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) FOR GEOGRAPHIC ATROPH

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2368058949?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-09-19 07:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2368058949","market":"us","top_or_hot":-1,"title":"BRIEF-Astellas Pharma Inc: Iveric Bio Announces Positive 24-Month Topline Results From Phase 3 Study Of Izervay (Avacincaptad Pegol Intravitreal Solution) For Geographic Atroph","media":"Reuters","content":"<html><body><p>Sept 19 (Reuters) - Astellas Pharma Inc   :</p><p>   * ASTELLAS PHARMA INC - IVERIC BIO ANNOUNCES POSITIVE 24-MONTH TOPLINE RESULTS FROM PHASE 3 STUDY OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) FOR GEOGRAPHIC ATROPH</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Astellas Pharma Inc: Iveric Bio Announces Positive 24-Month Topline Results From Phase 3 Study Of Izervay (Avacincaptad Pegol Intravitreal Solution) For Geographic Atroph</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Astellas Pharma Inc: Iveric Bio Announces Positive 24-Month Topline Results From Phase 3 Study Of Izervay (Avacincaptad Pegol Intravitreal Solution) For Geographic Atroph\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-19 07:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 19 (Reuters) - Astellas Pharma Inc   :   * ASTELLAS PHARMA INC - IVERIC BIO ANNOUNCES POSITIVE 24-MONTH TOPLINE RESULTS FROM PHASE 3 STUDY OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISEE","symbol_name":"IVERIC bio Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2368058949","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2368058949","pubTimestamp":1695078155,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 19 (Reuters) - Astellas Pharma Inc   :   * ASTELLAS PHARMA INC - IVERIC BIO ANNOUNCES POSITIVE 24-MONTH TOPLINE RESULTS FROM PHASE 3 STUDY OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) FOR GEOGRAPHIC ATROPHSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISEE":"IVERIC bio Inc","BK4139":"生物科技"},"translate_title":"简介——Astellas Pharma Inc。：Iveric Bio宣布Izervay（Avacincaptad Pegol玻璃体内溶液）治疗地理萎缩的3期研究的24个月顶线结果为阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISEE":0.9},"content_text":"Sept 19 (Reuters) - Astellas Pharma Inc   :   * ASTELLAS PHARMA INC - IVERIC BIO ANNOUNCES POSITIVE 24-MONTH TOPLINE RESULTS FROM PHASE 3 STUDY OF IZERVAY (AVACINCAPTAD PEGOL INTRAVITREAL SOLUTION) FOR GEOGRAPHIC ATROPHSource text for Eikon:    Further company coverage:","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2368058949"}